Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Hodgkin's Disease, Malignant Lymphomas High Grade, Chemoresistance
Both
Hodgkin's Disease, Malignant Lymphomas High Grade, Chemoresistance
Trial Information
Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade
Inclusion Criteria:
- initial Attainment: High-grade NHL or Hodgkin's disease all stages:I, II, III et IV.
- Relapse: High-grade NHL or Hodgkin's disease relapse in all stages:I, II, III et IV.
- Patients recruited by the Network of clinical hematology du Limousin
- Patients older than 18 years with or without brain damage
Exclusion Criteria:
- Pregnant women or nursing mothers or without effective contraception
- Patients without coverage by social security
- Patients who started steroids referred to antitumor
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To evaluate the predictive value of fixing the MIBI by the masses lymphomatous or Hodgkiniennes (initial or repeated) on the response to chemotherapy in 4 months.
Principal Investigator
Jacques MONTEIL, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital, Limoges
Authority:
French : DGS
Study ID:
I04016
NCT ID:
NCT00551798
Start Date:
March 2005
Completion Date:
January 2011
Related Keywords:
- Hodgkin's Disease
- Malignant Lymphomas High Grade
- Chemoresistance
- Hodgkin's Disease
- Malignant lymphomas high grade
- Chemoresistance
- MIBI
- PGP
- MRP1
- Tumor response
- Hodgkin Disease
- Lymphoma
Name | Location |
|---|
